DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Tamara L LotanHarsimar B KaurAbdullah M AlharbiColin C PritchardJonathan I EpsteinPublished in: Histopathology (2019)
These data are consistent with emerging data showing that DNA repair alterations are enriched among castration-resistant prostate cancer and aggressive subsets of primary tumours. Given that these patients are potential candidates for poly(ADP-ribose) polymerase inhibitor and/or immune checkpoint blockade, and have a poor prognosis with standard therapy, we recommend that tumour and germline DNA sequencing with or without mismatch repair protein immunohistochemistry be considered for all prostatic adenocarcinomas with focal pleomorphic giant-cell features.
Keyphrases
- giant cell
- dna repair
- dna damage
- poor prognosis
- long non coding rna
- end stage renal disease
- electronic health record
- dna damage response
- oxidative stress
- ejection fraction
- newly diagnosed
- benign prostatic hyperplasia
- chronic kidney disease
- big data
- prognostic factors
- peritoneal dialysis
- radical prostatectomy
- machine learning
- single cell
- single molecule
- peripheral blood
- circulating tumor
- climate change
- risk assessment
- protein protein
- nucleic acid
- cell therapy
- squamous cell
- structural basis